List of Contents

Nucleic Acid Therapeutics Market Size, Share, and Trends 2024 to 2033

Nucleic Acid Therapeutics Market (By Products: Anti-sense Oligonucleotides (ASOs) and DNA Aptamers, RNA Interference [RNAi] and Short Interfering RNAs [siRNAs], Others; By Application: Monogenetic Disorders, Multi-Genetic Disorders; By End User: Hospitals and Clinics, Academic and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : June 2024
  • Report Code : 4385
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Nucleic Acid Therapeutics Market 

5.1. COVID-19 Landscape: Nucleic Acid Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Nucleic Acid Therapeutics Market, By Products

8.1. Nucleic Acid Therapeutics Market Revenue and Volume, by Products, 2024-2033

8.1.1 Anti-sense Oligonucleotides (ASOs) and DNA Aptamers

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Nucleic Acid Therapeutics Market, By Application

9.1. Nucleic Acid Therapeutics Market Revenue and Volume, by Application, 2024-2033

9.1.1. Monogenetic Disorders

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Multi-Genetic Disorders

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Nucleic Acid Therapeutics Market, By End User 

10.1. Nucleic Acid Therapeutics Market Revenue and Volume, by End User, 2024-2033

10.1.1. Hospitals and Clinics

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Academic and Research Institutes

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Nucleic Acid Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)

Chapter 12. Company Profiles

12.1. Genzyme

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Sanofi

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Piezo Therapeutics

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Transcode Therapeutics

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. NOVARTIS AG.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Aldevron

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Switch Therapeutics

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Sarpeta Therapeutics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Qaigen NV

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Impilo Therapeutics

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us